Microsatellite Instability
Information
- Disease name
- Microsatellite Instability
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03228667 | Active, not recruiting | Phase 2 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | December 11, 2018 | December 2024 |
| NCT05257057 | Active, not recruiting | Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome | May 8, 2019 | December 2024 | |
| NCT03519412 | Active, not recruiting | Phase 2 | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | January 23, 2019 | December 2024 |
| NCT05511688 | Active, not recruiting | National Cohort of Colorectal Cancers With Microsatellite Instability | March 22, 2017 | October 2022 | |
| NCT06238193 | Completed | Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer | January 1, 2003 | January 1, 2024 | |
| NCT03053466 | Completed | Phase 1 | APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | March 27, 2017 | February 25, 2022 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT03012581 | Completed | Phase 2 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | June 16, 2017 | November 11, 2023 |
| NCT03935893 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | December 3, 2019 | June 30, 2037 |
| NCT04817826 | Recruiting | Phase 2 | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. | April 1, 2021 | April 30, 2025 |
| NCT03594448 | Recruiting | Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients | September 5, 2018 | September 5, 2025 | |
| NCT03767348 | Recruiting | Phase 2 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | September 20, 2017 | November 2024 |
| NCT03827044 | Terminated | Phase 3 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer | August 31, 2018 | January 5, 2022 |
| NCT04106167 | Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | June 11, 2019 | August 11, 2023 | |
| NCT04191252 | Unknown status | Genetic Mutation in Epithelial Ovarian Cancer | December 19, 2019 | January 1, 2023 | |
| NCT04191226 | Unknown status | Genetic Mutation in Recurrent Cervical Cancer | December 19, 2019 | January 1, 2023 | |
| NCT03744962 | Unknown status | MSI in Circulatory DNA of Endometrial Cancer | November 10, 2018 | December 23, 2020 | |
| NCT03447431 | Unknown status | Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact | April 5, 2018 | February 2021 | |
| NCT02966587 | Withdrawn | Phase 2 | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | May 15, 2018 | May 15, 2023 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D053842